DUBLIN — April 2, 2020 — Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it has acquired Curzion Pharmaceuticals, Inc., a privately held development-stage biopharma company, and its development-stage oral...
A drug that could raise IQ – Balance Therapeutics raises $18M, conducting Down Syndrome trials
MedCity News, March 19, 2015 – Stanford spinout Balance Therapeutics just raised $18 million for its therapy that could raise the IQ of people with intellectual disability. It’s using a small molecule drug that has been around for decades – GABA-A antagonists – but rationalizes the approach by delving deeper into the molecular underpinnings of what causes diseases like Down Syndrome and dementia.
And it could improve the IQ of a person with Down Syndrome 10 to 20 percent.
